Over 1,000 Chemotherapy Protocols And Counting
New chemotherapy protocols are added weekly. All protocols are reviewed by Medical Oncologists and Hematologists.
New Reference: Tafasitamab with Rituximab/Lenalidomide for Rel/Ref Follicular Lymphoma
The addition of tafasitamab to lenalidomide and rituximab significantly improved progression-free survival and overall response rate compared to the placebo group. The treatment wa
New Drug: Suvemcitug for Ovarian Cancer
The SCORES trial demonstrated that suvemcitug, when added to chemotherapy, significantly improved progression-free and overall survival in women with platinum-resistant ovarian can
New Drug: Savolitinib with Osimertinib for EGFR-Mutated, MET-Amplified NSCLC
Savolitinib-osimertinib significantly prolonged progression-free survival compared to chemotherapy in EGFR mutation-positive, MET-amplified Chinese NSCLC patients. The combination
New Indication: Ribociclib + Letrozole for Low-Grade Serous Ovarian Cancer
Ribociclib plus letrozole achieved a 30.6% overall response rate, with a median progression-free survival of 14.5 months and median overall survival of 44.5 months. The regimen dem
New Reference: Pirtobrutinib vs. Ibrutinib in CLL
Pirtobrutinib was shown to be non-inferior to ibrutinib in terms of overall response rate and had a more favorable safety profile, with lower rates of adverse cardiac events. The s
New Indication: Pirtobrutinib for Untreated CLL without del(17p)
Pirtobrutinib showed superior progression-free survival compared to bendamustine plus rituximab with a hazard ratio of 0.199. It was well tolerated with significantly fewer adverse
New Protocol: Neoadjuvant Low-dose Pembrolizumab for Triple-Negative Breast Cancer
The PLANeT trial demonstrated that the addition of low-dose pembrolizumab (50 mg every 6 weeks) to standard chemotherapy significantly increased pathological complete response rate
New Reference: Adjuvant Nivolumab for Muscle-Invasive Bladder Cancer
The study found that adjuvant nivolumab significantly improved disease-free survival compared to placebo in patients with high-risk muscle-invasive urothelial carcinoma. The analys
New Protocol: Adjuvant Nivolumab with CISplatin Concurrently with Radiotherapy for Head and Neck Cancer
Adding nivolumab to cisplatin and radiotherapy significantly improved disease-free survival for high-risk resected LA-SCCHN. Nivolumab reduced locoregional relapses with a moderate
